Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial
Salah-Eddin Al-Batran,Nils Homann,Claudia Pauligk,Gerald Illerhaus,Uwe M. Martens,Jan Stoehlmacher,Harald Schmalenberg,Kim Barbara Luley,Nicole Prasnikar,Matthias Egger,Stephan Probst,Helmut Messmann,Markus Moehler,Wolfgang Fischbach,Jörg T. Hartmann,Frank Mayer,Heinz-Gert Höffkes,Michael Koenigsmann,Dirk Arnold,Thomas Kraus,Kersten Grimm,Stefan Berkhoff,Stefan Post,Elke Jäger,Wolf O. Bechstein,Ulrich Ronellenfitsch,Stefan Mönig,Ralf Hofheinz +27 more
Reads0
Chats0
TLDR
Patients with limited metastatic disease who received neoadjuvant chemotherapy and proceeded to surgery showed a favorable survival, and the AIO-FLOT3 trial provides a rationale for further randomized clinical trials.Abstract:
Importance Surgical resection has a potential benefit for patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction. Objective To evaluate outcome in patients with limited metastatic disease who receive chemotherapy first and proceed to surgical resection. Design, Setting, and Participants The AIO-FLOT3 (Arbeitsgemeinschaft Internistische Onkologie–fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial is a prospective, phase 2 trial of 252 patients with resectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Patients were enrolled from 52 cancer care centers in Germany between February 1, 2009, and January 31, 2010, and stratified to 1 of 3 groups: resectable (arm A), limited metastatic (arm B), or extensive metastatic (arm C). Data cutoff was January 2012, and the analysis was performed in March 2013. Interventions Patients in arm A received 4 preoperative cycles of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) followed by surgery and 4 postoperative cycles. Patients in arm B received at least 4 cycles of neoadjuvant FLOT and proceeded to surgical resection if restaging (using computed tomography and magnetic resonance imaging) showed a chance of margin-free (R0) resection of the primary tumor and at least a macroscopic complete resection of the metastatic lesions. Patients in arm C were offered FLOT chemotherapy and surgery only if required for palliation. Patients received a median (range) of 8 (1-15) cycles of FLOT. Main Outcomes and Measures The primary end point was overall survival. Results In total, 238 of 252 patients (94.4%) were eligible to participate. The median (range) age of participants was 66 (36-79) years in arm A (n = 51), 63 (28-79) years in arm B (n = 60), and 65 (23-83) years in arm C (n = 127). Patients in arm B (n = 60) had only retroperitoneal lymph node involvement (27 patients [45%]), liver involvement (11 [18.3%]), lung involvement (10 [16.7%]), localized peritoneal involvement (4 [6.7%]), or other (8 [13.3%]) incurable sites. Median overall survival was 22.9 months (95% CI, 16.5 to upper level not achieved) for arm B, compared with 10.7 months (95% CI, 9.1-12.8) for arm C (hazard ratio, 0.37; 95% CI, 0.25-0.55) ( P Conclusions and Relevance Patients with limited metastatic disease who received neoadjuvant chemotherapy and proceeded to surgery showed a favorable survival. The AIO-FLOT3 trial provides a rationale for further randomized clinical trials. Trial Registration clinicaltrials.gov identifier:NCT00849615read more
Citations
More filters
Journal ArticleDOI
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer.
Lorenzo Fornaro,Caterina Vivaldi,A. Parnofiello,Clara Ugolini,Giuseppe Aprile,Giovanna De Maglio,Irene Pecora,Donatella Iacono,Francesca Crivelli,Silvia Catanese,Giovanni Gerardo Cardellino,Monica Lencioni,Enrico Vasile,Francesca Salani,Mario Clerico,Lorenzo Calvetti,Alfredo Falcone,Gianpiero Fasola,Gabriella Fontanini,Francesco Montagnani +19 more
TL;DR: A simple nomogram based on always-available pathologic information accurately predicts the probability of HER2 positivity in GOC.
Journal ArticleDOI
Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position
Antonin Levy,Anna Dorothea Wagner,Cyrus Chargari,Markus Moehler,Marcel Verheij,Jérôme Durand-Labrunie,Manon Kissel,Erick Chirat,Pascal Burtin,Michel Ducreux,Valérie Boige,Magnus Nilsson,Narikazu Boku,Ian Chau,Eric Deutsch +14 more
TL;DR: A decision-making process is proposed and randomised trials for the management of malignant dysphagia in metastatic oesogastric cancer patients are highlighted to highlight the role of oesophageal brachytherapy.
Journal ArticleDOI
Current status of perioperative chemotherapy for locally advanced gastric cancer and JCOG perspectives.
Masanori Terashima,Takaki Yoshikawa,Narikazu Boku,Seiji Ito,Akira Tsuburaya,Yoshiaki Iwasaki,Takeo Fukagawa,Masanori Tokunaga,Takeshi Sano,Mitsuru Sasako +9 more
TL;DR: A prospective cohort study to evaluate the validity of clinical staging in JCOG1302A and cT3-4 and cN1-3 are selected as optimal candidate for perioperative chemotherapy, to demonstrate the superiority of peri operative chemotherapy to adjuvant chemotherapy.
Journal ArticleDOI
Chinese consensus on the diagnosis and treatment of gastric cancer with liver metastases.
Kecheng Zhang,Lin Chen +1 more
TL;DR: A new clinical classification system, the Chinese Type for Gastric Cancer Liver Metastases, is developed, based on the likelihood of a surgical treatment being successful, and the MDT mode should be implemented throughout all treatment of GCLM.
Journal ArticleDOI
2221 Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer; short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG 0501)
Masanori Terashima,Y. Iwasaki,Junki Mizusawa,H. Katayama,Kenichi Nakamura,Hitoshi Katai,Takaki Yoshikawa,Seiji Ito,M. Kaji,Yutaka Kimura,M. Hirao,M. Yamada,Akira Kurita,Masakazu Takagi,Masahiro Goto,Akinori Takagane,H. Yabuzaki,Naoki Hirabayashi,Takeshi Sano,Mitsuru Sasako +19 more
TL;DR: NAC for type 4 and large type 3 gastric cancer followed by D2 gastrectomy can be safely performed without increasing the morbidity or mortality.
References
More filters
Journal ArticleDOI
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal ArticleDOI
New guidelines to evaluate the response to treatment in solid tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: In this article, the authors proposed a model by which a combined assessment of all existing lesions, characterized by target lesions (to be measured) and nontarget lesions, is used to extrapolate an overall response to treatment.
Journal ArticleDOI
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Salah-Eddin Al-Batran,Ralf Hofheinz,Claudia Pauligk,Hans-Georg Kopp,Georg Martin Haag,Kim Barbara Luley,Johannes Meiler,Nils Homann,Sylvie Lorenzen,Harald Schmalenberg,Stephan Probst,Michael Koenigsmann,Matthias Egger,Nicole Prasnikar,Karel Caca,Jörg Trojan,Uwe M. Martens,Andreas Block,Wolfgang Fischbach,Rolf Mahlberg,Michael R. Clemens,Gerald Illerhaus,Katja Zirlik,Dirk Behringer,Wolff Schmiegel,Michael Pohl,Michael Heike,Ulrich Ronellenfitsch,Martin Schuler,Wolf O. Bechstein,Alfred Königsrainer,Timo Gaiser,Peter Schirmacher,Wael Hozaeel,Alexander Reichart,Thorsten Oliver Goetze,Mark Sievert,Elke Jäger,Stefan Mönig,Andrea Tannapfel +39 more
TL;DR: Findings from the phase 2 part of the FLOT4 trial, which compared histopathological regression in patients treated with a docetaxel-based triplet chemotherapy versus an anthracycline-based doublet chemotherapy before surgical resection, suggest FLOT was associated with significantly higher proportions of patients achieving pathological complete regression than was ECF/ECX.
Journal ArticleDOI
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial
Kazumasa Fujitani,Han-Kwang Yang,Junki Mizusawa,Young-Woo Kim,Masanori Terashima,Sang-Uk Han,Yoshiaki Iwasaki,Woo Jin Hyung,Akinori Takagane,Do Joong Park,Takaki Yoshikawa,Seokyung Hahn,Kenichi Nakamura,Cho Hyun Park,Yukinori Kurokawa,Yung-Jue Bang,Byung Joo Park,Mitsuru Sasako,Toshimasa Tsujinaka +18 more
TL;DR: Since gast rectomy followed by chemotherapy did not show any survival benefit compared with chemotherapy alone in advanced gastric cancer with a single non-curable factor, gastrectomy cannot be justified for treatment of patients with these tumours.
Journal ArticleDOI
Value of palliative resection in gastric cancer.
TL;DR: Non‐curatively treated patients from the Dutch Gastric Cancer Trial were studied to define more accurately which patients might benefit from palliative resection.